Theralase(r) grants stock options

Toronto, on / accesswire / september 21, 2023 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light activated photo dynamic compounds ("pdcs"), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers, announces the grant of stock options. the company has granted an aggregate of 360,000 stock options to certain directors and employees pursuant to the company's stock option plan.
CAN Ratings Summary
CAN Quant Ranking